Table 3. Adverse events reported by ≥10% of patients for 12 weeks after initiation of gemcitabine.
| Event, n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total, n (%) |
|---|---|---|---|---|---|
| Neutropenia | 3(25.0%) | 5(41.7%) | 2(16.7%) | 1(8.3%) | 11(91.7%) |
| Leukopenia | 2(16.7%) | 8(66.7%) | 0 | 0 | 10(83.3%) |
| Thrombocytopenia | 5(41.7%) | 1(8.3%) | 0 | 0 | 6(50.0%) |
| Infection | 0 | 3(25.0%) | 2(16.7%) | 0 | 5(41.7%) |
| Hb decrease | 2(16.7%) | 2(16.7%) | 0 | 0 | 4(33.3%) |
| Hypoalbuminemia | 3(25.0%) | 1(8.3%) | 0 | 0 | 4(33.3%) |
| Fatigue | 3(25.0%) | 1(8.3%) | 0 | 0 | 4(33.3%) |
| ALT increase | 4(33.3%) | 0 | 0 | 0 | 4(33.3%) |
| AST increase | 2(16.7%) | 1(8.3%) | 0 | 0 | 3(25.0%) |
| Oral mucositis | 2(16.7%) | 0 | 0 | 0 | 2(16.7%) |
| GGT increase | 2(16.7%) | 0 | 0 | 0 | 2(16.7%) |
| ALP increase | 2(16.7%) | 0 | 0 | 0 | 2(16.7%) |
| Anorexia | 2(16.7%) | 0 | 0 | 0 | 2(16.7%) |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Hb, hemoglobin.